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1  | INTRODUC TION
Bone health in men is a partially neglected health issue as it is less 
investigated than in the female counterpart.1-3 Even the clinical tri-
als investigating the efficacy of bone active drugs involve a smaller 
number of men than females, and not all of these drugs, which are 
available on the market for the treatment of female osteoporo-
sis, have been approved also for men by regulatory agencies.3,4 At 
present, evidence from several studies has unequivocally proved 
that male osteoporosis (a) is often secondary to other clinical 
conditions,3,5 (b) occurs later in life compared with women in the 
majority of cases,3 and (c) osteoporotic fractures are associated 
with higher morbidity and mortality in elderly men compared with 
women.1,6,7 Among secondary osteoporosis, male hypogonadism 
is one of the most important risk factors and accounts for the pro-
gressive bone loss in aging men, especially in case of a diagnosis of 
late-onset hypogonadism (LOH).1,8 Serum testosterone (T), in fact, 
decreases with advancing age in elderly men, and the amount of 
serum estradiol (E2) tends to decrease accordingly9; the same oc-
curs for bone loss during aging.1-3 Traditionally, T was considered 
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Abstract
Background: Bone health is underdiagnosed and undermanaged in men. Bone loss 
occurs in men with hypogonadism and in aging men. Thus, patients with a diagno-
sis of late-onset hypogonadism (LOH) are at risk of osteoporosis and osteoporotic 
fractures.
Objectives: To provide an update on research data and clinical implications regarding 
bone health in men with LOH by reviewing literature articles on this issue.
Materials and Methods: A thorough search of listed publications in PubMed on bone 
health in older men with hypogonadism was performed, and other articles derived 
from these publications were further identified.
Results: Late-onset Hypogonadism may be associated with reduced bone mineral 
density (BMD). In a pathophysiological perspective, the detrimental effects of testos-
terone (T) deficiency on BMD are partly ascribed to relative estrogen deficiency and 
both serum T and serum estradiol (E2) need to be above 200 ng/dL and 20 pg/mL to 
prevent bone loss. The effects of exogenous T on BMD are controversial, but most of 
the studies confirm that testosterone replacement therapy (TRT) increases BMD and 
prevents further bone loss in men with hypogonadism. No data are available on TRT 
and the prevention of fractures.
Discussion and Conclusion: In men with documented LOH, a specific clinical workup 
should be addressed to the diagnosis of osteoporosis in order to program subsequent 
follow-up and consider specific bone active therapy. TRT should be started according 
to guidelines of male hypogonadism while keeping in mind that it may also have posi-
tive effects also on bone health in men with LOH.
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the main sex steroid acting on male bone, but starting from the 
nineties the pivotal role exerted by estrogens started to rise10-13 
thanks to the description of the first cases of men with congenital 
estrogen deficiency due to estrogen resistance14 and aromatase 
deficiency.15,16 The observation that a condition of severe estro-
gen deficiency was constantly associated with the arrest of skel-
etal maturation and with severe bone loss resulting in osteopenia 
or osteoporosis in adult men with these rare diseases17,18 opened 
the way to fully understand the role of estrogens on bone as well 
as on other male physiological processes.12,19-22
2  | PATHOPHYSIOLOGY OF T DEFICIENCY 
AND ITS METABOLITES IN BONE
Sex steroids, both androgens and estrogens, exert direct and in-
direct effects on bone tissue and regulate bone homeostasis.23-25 
Estrogens derive from androgens after the aromatization of the A 
ring of androgens through the activity of the CYP19A1 enzyme, 
named aromatase, which is expressed in many male tissues.11,12,26
2.1 | Effects of T on bone
T exerts direct and indirect effects on bone.27-30 Direct effects 
of T involve several cells within the bone; among them, human 
mesenchymal stem cells, osteoblasts, and osteocytes express the 
androgen receptor and are target cells for T31; vice versa, oste-
oclasts are not target cells for direct action of T and androgens 
regulate osteoclast proliferation and activity indirectly through 
the modulation of the receptor activator of nuclear factor κ-B 
(RANK ligand).27 T and its metabolite dihydrotestosterone (DHT) 
exert anabolic action on osteocytes and osteoblasts by promot-
ing cell proliferation and probably also their differentiation,32 but 
the latter effect is less clear.27,28 Furthermore, T inhibits apopto-
sis of osteoblasts.33 Locally produced androgens (ie, DHT) within 
the bone contribute together with the circulating quote to support 
the direct effect of androgens on bone and account for different 
percentages of sex steroids within the tissue compared with blood 
concentration.29
Indirect effect of androgens on bone cells may be mediated by 
several cytokines and by the local production of growth hormone 
(GH) and insulin-like growth factor 1 (IGF-1) that are known to be 
under the control of T.27 Other indirect effects on bone are mediated 
by the mechanical load exerted by the muscle masses surrounding 
the bone. As muscle mass depends on serum T and hypogonadism 
leads to sarcopenia, this indirect effect is of great relevance for bone 
homeostasis.1,34,35 Both hypogonadism19,36 and aging37 lead to phys-
iological reduction in body muscle masses and sarcopenia in older 
men, thus promoting bone loss due to mechanical strain38 and pos-
tural instability, thus increasing the risk of fracture due to osteopo-
rosis or increased incidence of falls38,39 due to altered muscle–bone 
cross talk.40
2.2 | Effects of E2 on bone
Estrogens in men exert their action through the binding to the ERs. 
Nuclear ER alpha and ER beta and the transmembrane G protein–
coupled receptor GPR30 (GPER30) are expressed in human male 
tissue. The nuclear receptors account for genomic effects of estro-
gens, while the GPR30 transmembrane receptor accounts for non-
genomic, rapid effects of estrogens.11,12,26
In men, locally produced estrogens in bone come from andro-
gens thanks to aromatase that is expressed in fibroblasts and other 
bone cells (ie, osteoblasts and osteoclasts)12,41; the same occurs in 
tissues surrounding the bone such as the adipose tissue and the 
bone marrow.26 Circulating estrogens as well as locally produced 
estrogens exert their effect on bone through the binding to both ER 
alpha and ER beta that are expressed in the following bone cells: os-
teoblasts, osteoclasts, and osteocytes,42 all these cell types express 
also GPER30.43,44 Furthermore, estrogens increase osteocytes vital-
ity and inhibit their apoptosis,45 induce apoptosis of osteoclasts,46 
and inhibit their differentiation through the modulation of RANKL.42 
The final result is the decrease in bone resorption operated by os-
teoclasts.47 On the contrary, estrogens promote/maintain bone 
formation by osteoblasts through an antiapoptotic effect48 and by 
stimulating their differentiation.49 Apart direct effects, estrogens 
modulate other hormones and cytokines involved in bone physi-
ology (indirect effects), among them the GH/IGF-1 network being 
one of the most important.50 Finally, estrogens positively modulate 
the bone response to mechanical strain51,52 similarly to what andro-
gens38,40 do.
2.3 | Late-onset Hypogonadism, relative estrogen 
deficiency, and osteoporosis in men
In men, serum T progressively declines with aging53 according to the 
decrease in testicular function, a condition which is common in el-
derly men.54 On average, serum T is below the lower end of the nor-
mal range in about 20% of the older men (>60 years)55 while remains 
within the normal range in the majority of them.54 There is, however, 
a great variability in the decline of both total serum T and free serum 
T, accounting for interindividual differences and diverse trajectories 
of T decline over time.56
The majority of large, prospective studies involving aging 
men such as the Baltimore Longitudinal Study of Aging (BLSA), 
the Massachusetts Male Aging Study (MMAS), the Osteoporotic 
Fractures in Men Study (MrOS), the European Male Aging Study 
(EMAS), the Rancho Bernardo Study (RBS), the InCHIANTI Study, 
the Tromsø Study, the Concord Health and Ageing in Men Project 
(CHAMP), and the Health in Men Study (HIMS) found, on average, a 
decline of total serum T around 3 ng/dL per year57,58 in aging men,9 
which involves also both calculated serum-free T and serum-free T 
assayed by equilibrium dialysis.9 This finding results in an increase 
in the prevalence of biochemical hypogonadism with advancing 
age.9,54 The diagnosis of LOH, however, involves only a minority 
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of cases of older men with low serum T, depending on the sever-
ity of serum T deficiency, the presence of symptoms of hypogo-
nadism, and concomitant comorbidities that may lead to functional 
hypogonadism.9,54,59,60
In men with LOH, the reduced amount of T precursor avail-
able for aromatization into E2 may result in relative estrogen defi-
ciency,61 which may prompt the acceleration of the physiological 
process of bone loss occurring in aging.34,62,63 By an elegant study 
design, Finkelstein et al proved that the pharmacologically induced 
serum T decrease below 200 ng/dL is constantly associated with a 
corresponding serum E2 fall below 10 pg/mL and with significant 
changes in both bone turnover markers and BMD20 (Figure 1). This 
study proves that relative estrogen deficiency occurs in hypogo-
nadal men and that it is responsible to a great extent for bone loss, 
whereas T deficiency has a minor direct role.20 Outside the context 
of experimental design of pharmacologically induced hypogonad-
ism, both serum T and serum E2 decline with advancing age64-66 as 
demonstrated by both the MrOS and the EMAS. The occurrence of 
relative estrogen deficiency in aging men with LOH may depend on 
several factors.61 First, the severity of hypogonadism obviously in-
fluences the amount of circulating serum E2. Second, several asso-
ciated clinical conditions may modulate aromatase expression and 
estrogen production.61,67-69 As an example, obesity may boost es-
trogen production even in the presence of low serum T in hypogo-
nadal men through an increased rate of aromatization of androgens, 
thus preventing both relative estrogen deficiency and bone loss.68 
Third, individual genetic differences may predispose to relative es-
trogen deficiency on equal serum T levels.1 Both polymorphisms of 
the ER-alpha gene70,71 and of the gene encoding for the aromatase 
enzyme72,73 are associated with bone loss in men. Individual genetic 
differences influencing the expression and activity of the aromatase 
enzyme have been well-characterized in recent years61,68,69,72,73 
(Figure 1). By using a genome-wide association study and Mendelian 
randomization analysis on a large number of men, several genetic 
variants of the aromatase enzyme resulted directly related to the 
amount of circulating E2 and BMD as the genetically determined in-
crease of 1 pg/mL of serum E2 corresponded to a BMD increase of 
0.048 standard deviation at lumbar spine.74 The same experimental 
design proved that serum E2 but not T has a causal effect also on 
bone fractures.75 The importance of relative estrogen deficiency as 
pathophysiological process explaining several changes occurring in 
hypogonadal men as well as the need of keeping serum T and serum 
E2 above a certain threshold was strengthened thanks to these 
well-designed studies (Figure 1). Estrogen-related bone loss in men 
occurs especially when serum E2 is very low, similarly to what hap-
pens to post-menopausal women.9 The first evidence came from 
cases of severe aromatase deficiency where characterized by serum 
E2 is undetectable leading to bone loss, 76 and exogenous E2 admin-
istration results in a dose-dependent increase in BMD.62 The thresh-
old for serum E2 below which the loss of BMD is relevant and the 
risk of osteoporosis and osteoporotic fractures increases has been 
estimated to be comprised between 15 and 20 pg/mL20,23,34,47,77-
83 (Figure 1). In older men with hypogonadism, serum E2 remains 
higher if compared to the quite undetectable levels in post-meno-
pausal older women (below 5 pg/mL),9 but it may fall below 20 pg/
mL,79 thus accounting for the development of osteopenia and osteo-
porosis. The threshold for serum T ensuring bone mass preservation 
seems to be 200 ng/dL20,79 (Figure 1).
3  | LOH AND BONE MINER AL DENSIT Y 
(BMD)
It is well known that mild-to-severe hypogonadism in young adult 
men is almost constantly associated with reduced BMD and osteo-
penia/osteoporosis.4,84,85 The effects of T on BMD remain, however, 
conflicting in elderly men who often display only slight reduction 
in circulating T that often is due to functional hypogonadism.60,86 
Several large cohort studies investigating sex steroids in aging men, 
such as the BLSA, the MMAS, the InCHIANTI, and the HIMS, did not 
record data about bone health; in particular, BMD and osteoporotic 
fractures were not investigated.9,87 Conversely, other large cohort 
studies have investigated the relationships between sex steroids 
and BMD in aging men1,2,8,9 showing that low serum T is associated 
with reduced BMD in older men with overt hypogonadism (total 
T < 230 ng/dL; ie, 8 nml/L) compared with eugonadal older men 
F I G U R E  1   Circulating sex steroids and bone pathophysiology in men: relationship between serum T, serum E2, individual factors 
involved in the conversion of T into E2, putative thresholds for serum T20,79 and serum E2,20,34,47,80-82 and bone health
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(EMAS)35,66,88 and that serum bioavailable T is directly correlated 
with BMD (RBS and the Tromsø Studies).89-91 Only few studies such 
as the CHAMP did not find any association among serum T, serum 
E2, SHBG, and bone health.92,93
Studies on the relationships between circulating sex steroids 
and osteoporotic fractures in aging men are scanty and provide 
conflicting results9 varying from no association (CHAMP and the 
Tromsø) between circulating sex steroids (total and free serum 
T, and serum E2) and fracture risk,90,93,94 to the association of an 
increased risk of non-vertebral osteoporotic fractures with both 
serum T and serum E2 such as in the MrOS.95 Thanks to studies 
performed in the last 20 years using immunometric assays1,2,34,96 
and those most recent using the gold standard liquid chroma-
tography-tandem mass spectrometry (LC-MS/MS)97-99 for serum 
E2 measurement the concept that E2 is the main sex steroid in-
volved in the control of BMD maintenance in adult and older men 
is now textbook knowledge21,34,44 (see above the paragraph on 
pathophysiology for more details). Accordingly, both cross-sec-
tional70,89,100-103 and longitudinal studies 77,104 have disclosed a 
direct relationship between serum E2, especially the bioavailable 
fraction, and BMD in men pointing out that relative estrogen de-
ficiency rather than serum T decline per se is involved in bone 
loss.1,34,44 Among them, the most important are the EMAS,88 
RBS,89,105 and the MrOS.64 In addition, the latter study showed 
also a direct role of serum E2 on fracture risk.95
In clinical practice, serum T, serum E2, and SHBG should be con-
sidered, however weak predictors of vertebral fractures in older 
men.106 It should be considered, in fact, that most of these large co-
hort studies were not specifically addressed to investigate the rela-
tionships between sex steroids and bone as their primary endpoint, 
thus often failed to find an association.9 Almost all the studies that 
had as primary endpoint the investigation of the role of sex steroids 
on bone in men have clearly demonstrated that low-circulating T is 
associated with low BMD.77,102,107,108
4  | BONE HE ALTH: CLINIC AL APPROACH 
IN MEN WITH LOH
Andrological consultation is a good opportunity to check general 
health status in men, including bone.4
In the presence of a diagnosis of LOH, the investigation of bone 
health becomes mandatory.4,5 The first step is represented by the 
clinical interview, which should keep information on past medical his-
tory with particular concern to general health and physical changes, 
endocrinological issues, lifestyle, ongoing or previous medications, 
and additional risk factors for osteoporosis (ie, comorbidities) other 
than hypogonadism4 (Figure 2). Physical examination should check 
the presence of skeletal features associated with hypogonadism, 
such as eunuchoid skeletal proportions and the body composition 
F I G U R E  2   Information and issues to be covered during medical interview and at each visit
Medical 
history
Endocrinological history (-Delayed puberty; -Previous hypogonadism)
History of previous fractures (-Atraumatic; -Low trauma)
Osteoporosis or fractures history among relatives
General 
health
Reduction of stature
Bone pain/Back pain
Tendency to fall/Postural equilibrium
Lifestyle
Physical activity/Sedentary lifestyle/Food intake/Undernutrition
Alcohol/Recreative drugs
Smoking
Comorbidites
Endocrine diseases (-acromegaly; -Cushing syndrome; -hyperPTH, -diabetes mellitus, 
isolated Vitamin D deficiency)
Infectious diseases (-HIV; -viral hepatitis)
Malabsorption (-celiac diseases; -bariatric surgery; -IBD)
Other (-COPD; -reumathologic diseases; -chronic kidney disease; iron overload)
Medications
Glucocorticoids/Chemoterapeutics/Anticonvulsants/ADT
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paying particular attention to the presence of reduced muscle 
mass (sarcopenia), which is common in hypogonadal men.19,40,109 
Furthermore, specific features related to severe osteoporosis should 
be ruled out. Among them, height changes, kyphosis, wall-to-occiput 
distance (>0 cm), rib-to-pelvis distance (<3 fingers), and tooth loss110 
are simple signs that may suggest osteoporosis and possible occult 
vertebral fractures.4,111
4.1 | Clinical examinations
In order to investigate bone health status in men with LOH, further 
biochemical, hormonal, and imaging examination may be performed.
4.2 | Sex steroid measurements
Biochemical examinations should be addressed to gonadotro-
pins, T, and SHBG for the diagnosis of LOH, according to available 
guidelines.60,112
As previously outlined, relative estrogen deficiency is clinically rele-
vant for the development of osteopenia/osteoporosis in older men with 
LOH,1,20,61,68 but the measurement of serum E2 is not recommended in 
clinical practice as the commercially available assays are not accurate 
for measuring low values typical of men (20-40 pg/mL),4,13,61,113 thus 
leaving the diagnosis of relative estrogen deficiency in men with hy-
pogonadism still challenging.61 Having serum E2 measured at baseline 
may help, theoretically, to better stratify the risk of fracture and the 
effectiveness of TRT in normalizing not only serum T but also serum E2 
(Figure 1), higher BMD being associated with higher serum E2 within 
the normal range for men.68 Hopefully, the widespread diffusion of 
LC-MS/MS, which is the only accurate and reliable methodology,114,115 
among clinical laboratories116,117 together with the standardization of 
LC-MS/MS reference ranges for serum sex steroids,117 will probably 
lead to the validation of this technique for the measurement of serum 
E2 in men also for clinical purposes in the next future.
At present, the measurement of serum E2 is not recommended 
in men in the diagnostic workup of osteoporosis,4,112 hypogonad-
ism,60,112,118,119 and in general in the routine, clinical assessment of 
the male patient61 remaining confined to research or clinical settings 
for which the LC-MS/MS measurement is available or in rare cases in 
which one of the most accurate immunometric assays is available.120 
Only in this setting, serum E2 may be useful to rule out/rule in rela-
tive estrogen deficiency in a man with LOH and as a reliable target 
of TRT.1,34,61
4.3 | Biochemical evaluation of bone metabolism
In men with LOH and documented low BMD (osteopenia or osteo-
porosis), serum calcium, phosphorous, vitamin D, and parathyroid 
hormone (PTH) should be checked in order to rule out other disor-
ders of calcium/phosphorous metabolism.4,121,122
Measuring markers of bone turnover are not mandatory, and 
their use should be confined to the monitoring of the effects of bone 
active therapy even though no clear evidence about their usefulness 
in the clinic is available.4,123
4.4 | Imaging
The gold standard for obtaining information on bone health in men is 
dual-energy X-ray absorptiometry (DXA).4,111 This simple, safe, and 
rapid tool measures BMD at different skeletal sites (lumbar spine 
and femoral neck) and allows the diagnosis of osteopenia or oste-
oporosis when the t-score is between −1.0 and 2.5 or below −2.5, 
respectively.124,125 A DXA examination at both lumbar and femoral 
sites is mandatory for men with a long history of hypogonadism 1 and 
for older men with LOH and a serum T below 200 ng/dL as in these 
cases an impairment of BMD is highly probable4,5,20,79 (Figure 1). In 
men with LOH and serum T between 200 and 300 ng/dL, DXA at 
both lumbar and femoral sites is indicated in the presence of symp-
toms of hypogonadism or if other risk factors for osteoporosis are 
present (Figure 2). Pitfalls of DXA measurement should be taken into 
account in order to minimize errors in the diagnostic interpretation 
of DXA report. Among them, the most common are the coexistence 
of osteomalacia, previous fractures resulting in compacted bone tis-
sue, severe scoliosis, vertebral deformities (eg, osteophytes), and 
inadequate operating procedures (eg, machine calibration, patient's 
position).126
Other techniques for the measurement of BMD such as ul-
trasound and quantitative computed tomography (QCT) are 
not validated in clinical practice and are only useful in research 
settings.4,5,111,125,127
X-ray of the spine is a simple and inexpensive examination, which 
is mandatory for patients with back pain or with documented signs 
or symptoms of reduction in height of the spine, such as height or 
abnormal wall-to-occiput distance4,110 (Figure 2). X-ray of the spine 
allows confirming the diagnosis of severe osteoporosis while it is not 
useful for the diagnosis of osteopenia or osteoporosis.4 Furthermore, 
X-ray of the spine allows better characterizing the type and severity 
of fracture according to the Genant classification of vertebral frac-
tures128 (https://www.iofbo nehea lth.org/radio logic al-asses sment 
-and-bone-turno ver-markers).
4.5 | Fracture risk in men with LOH
Fracture risk assessment needs a careful collection of information 
from the male patient with a diagnosis of LOH in order to rule in/
rule out additional risk factors that may modify the risk stratification 
(Figure 2).
All available data may be pooled all together in order to cal-
culate the cumulative risk of fracture by using the Fracture 
Risk Assessment Tool (FRAX)® (https://www.sheff ield.ac.uk/
FRAX/).129 At the condition that the patient's interview is 
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well-conducted and all information is available (Figure 2), FRAX is 
a simple and effective tool able to predict fracture risk in men both 
when BMD values are included130 or not131 allowing to identify pa-
tients at high risk to develop fractures132 and to choose adequate 
therapeutic options.125
BMD measurement by DXA is also useful to establish the risk of 
fractures in men as low BMD is associated with an increased prev-
alence of future osteoporotic fractures at all sites in men.125,133,134 
Besides, change from baseline over time is able to predict future 
fractures in older men.135 Accordingly, a 10-year risk of hip and major 
osteoporotic fractures obtained by FRAX ≥ 3% ≥20%, respectively, 
is a good threshold useful to decide starting bone active therapy in 
men older than 50 years.125
5  | EFFEC TS OF T TRE ATMENT ON BONE 
IN LOH PATIENTS
During adulthood, bone mass remains the same in men after the 
achievement of the peak of bone mass and begins to decline only 
after the age of 50, with a significant bone loss starting around the 
age of 70.1,44,61,136 In young hypogonadal men, T replacement ther-
apy (TRT) prevents further bone loss and ensures the achievement 
of a physiological peak of bone mass.137 The role of TRT in older men 
is, however, more controversial. In uncontrolled studies, long-term 
TRT is able to improve BMD at both lumbar and femoral sites138-141 
or at the femoral site only in other research settings142 and to de-
crease markers of bone turnover.140 In older men with osteopenia 
or osteoporosis and concomitant documented hypogonadism, TRT 
leads to a greater increase in spine BMD in the treated group com-
pared with controls.143 The effects of TRT seem to be dose-depend-
ent,140 and there is evidence that even T administration to eugonadal 
men is able to increase BMD by bringing serum T to levels near the 
upper end of the normal range.144 Conversely, several studies did 
not find any significant effect of TRT on BMD145-147 and on bone 
turnover markers.148
Randomized controlled studies provided conflicting results. TRT 
is able to significantly decrease bone turnover markers compared 
with placebo,147 but no difference147 or only a small improvement149 
was found in BMD in some studies. On the contrary, other random-
ized, controlled studies found a significant increase in vertebral and 
femoral BMD in the TRT group compared with placebo150,151 cou-
pled with changes in bone markers.150
Meta-analyses of clinical studies/trials confirm that TRT is ef-
fective in increasing BMD at the lumbar spine152,153 and in improv-
ing markers of bone turnover.152 The effect of TRT at the femoral 
site remains doubtful even though a not significant positive trend 
has been shown.153 The effect of TRT on BMD remains at least 
doubtful as the patients enrolled in various studies were hetero-
geneous regarding the presence/absence and the severity of T de-
ficiency. Some studies enrolled patients with low-normal serum T 
above the lower end of the normal range (300 ng/dL)145,146,148 or 
patients with various degree of T deficiency ranging from severe 
(<100 ng/dL)138,154,155 to mild hypogonadism (between 200 and 
300 ng/dL).139-142,146,147,149,150,156 However, the heterogeneity of 
serum T at baseline among studies and among subjects enrolled in 
each study together with different study designs (duration, end-
points, methodologies) does not help to reach robust evidence on 
the effects of TRT on bone and further studies are needed. T trail 
performed on men older than 65 and documented serum T below 
275 ng/dL have found a significant effect of T on spine BMD and 
hip BMD.151 The efficacy of TRT on BMD increase probably is pro-
portional to the severity of hypogonadism and serum T at baseline 
and a greater effect on bone should be expected in men with very 
low serum T at baseline.
Antiestrogens (ie, aromatase inhibitors and estrogen receptor 
blockers) have been suggested as a possible therapeutic alter-
native to TRT in men with LOH, but their efficacy has not been 
proved to be equal to that of TRT, especially in long-term treat-
ment.157 Furthermore, the number of studies with antiestrogens 
is limited as well as safety data. For these reasons, antiestrogens 
remain off-label and are not recommended for the treatment of 
hypogonadism, including LOH.60,157 In men with LOH and concom-
itant osteopenia or osteoporosis, the use of antiestrogens may un-
balance the E/T ratio and cause relative estrogen deficiency and 
is not considered safe for preventing bone loss and ensure bone 
health.34,61 Accordingly, TRT increases BMD, but the aromatase 
inhibitor anastrozole did not in a study involving older men with 
low serum T158 and there is evidence that aromatase inhibitors can 
cause bone loss.157-159
For all these reasons, TRT alone must not be considered as a 
treatment for osteoporosis in older men with low serum T.4,60,160 In 
clinical practice, TRT should be offered to older men with a docu-
mented diagnosis of LOH according to available advice from clinical 
guidelines.60,112 TRT should be started after having informed and 
discussed with the patients about possible risk and benefits and ex-
pected outcomes of TRT.59,60,112,119,161 In the clinical context of LOH, 
TRT may have beneficial effects on bone health too, but an impaired 
bone status should not lead the decision to start TRT as the latter 
must be based on the complex of both signs and symptoms (not 
solely the impaired BMD) of hypogonadism together with the evalu-
ation of potential risks and benefits.4,60,84,112 TRT in men with LOH 
and osteoporosis may help preventing further bone loss and may 
increase BMD but to a lesser extent than bone active drugs.162 Of 
note, TRT has no documented effect on the prevention of fractures 
and for this reason cannot be considered a therapy for the treatment 
of osteoporosis. All formulations of exogenous T such as transder-
mal,138,156 oral,154 and intramuscular are able to act on bone.60,148 
Men with LOH treated with TRT should expect that TRT may help 
in preventing further bone loss and increase BMD especially in men 
with very low serum T at baseline.146 In order to have beneficial 
effects on bone, TRT should ensure serum T levels at least above 
200 ng/dL20,79 and, if accurate assays for estradiol are available, a 
serum E2 above 20 pg/mL1,34,61,68,69 in order to exert a protective 
role on bone (Figure 1). In this perspective, serum T and serum E2 
may be considered reliable targets of TRT for bone health.34,61,68
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6  | FOLLOW-UP
Follow-up of men with LOH should also be addressed to bone health 
in men with no osteopenia or osteoporosis at first or previous vis-
its, and interview focusing on bone health should be repeated at 
each visit (Figure 2). Furthermore, DXA remains the gold stand-
ard to monitor BMD over time and may be repeated every two to 
three years, depending on patient's health status and risk factors for 
osteoporosis.
In patients on treatment with active bone drugs, it is important 
to check about patient's compliance to therapy. Clinical investi-
gation should include regular measurement of calcium, vitamin 
D, and kidney function. Bone turnover markers may be useful 
for checking efficacy of bone active therapy even if they are not 
mandatory.
7  | PHYSIC AL AC TIVIT Y AND 
PRE VENTION OF FURTHER BONE LOSS
Among lifestyle changes that may be beneficial for bone health 
(Figure 2), physical activity merits to be considered in a comprehen-
sive way in men with LOH for its beneficial effects on muscle mass, 
skeletal trophism (see above the paragraph on pathophysiology for 
details), and its direct effects on T secretion. Accordingly, physical 
activity acts in a synergic fashion together with T by increasing and 
ensuring muscle mass and both the muscle contraction during physi-
cal activity and the muscle mass itself exert an anabolic action on 
bone through enhanced mechanical load.163-165 Besides, physical 
exercise is able to increase serum T after short time,166,167 thus sup-
porting the concept that physical activity and serum T take part to a 
virtuous circle able to prevent bone loss.165 In addition, physical ac-
tivity is effective in preventing falls in older patients.165 For all these 
reasons, the prescription of physical activity and exercise should be 
part of the therapeutic approach to the older man with LOH in order 
to ensure bone health and prevent fractures.4,165,168
8  | TRE ATMENT OF OSTEOPENIA /
OSTEOPOROSIS IN MEN WITH LOH
After the diagnosis of osteoporosis, a man with concomitant LOH 
requires a specific therapeutic approach which needs to be tailored 
according to patient's clinical data. In men with LOH and a diagnosis 
of osteoporosis, a specific treatment with a bone active drug is indi-
cated, according to guidelines and expert advices for the treatment 
of male osteoporosis.3-5,160 Among them, bisphosphonates (zole-
dronic acid, alendronate, risedronate, and pamidronate), teriparatide 
or PTH analogues, and denosumab are all approved by regulatory 
agencies for the treatment of osteoporosis in men.4,160 These drugs 
should be prescribed in association with calcium plus vitamin D sup-
plementation. In men, the treatment with calcium and vitamin D is 
indicated also in case of osteopenia when active bone therapy is not 
yet necessary.4,160,169 Lifestyle changes and behavioral advice aim-
ing to prevent falls are also indicated in men with osteoporosis.3-5
9  | UNRESOLVED ISSUES
The interpretation of DXA measurement in men suffers from the ab-
sence of normative values obtained from male populations. Most of 
the data used for obtaining reference ranges and for the calculation 
of t-scores come from female populations; thus, there is no consen-
sus on BMD-based definition of osteoporosis.1,170 Future studies 
are needed in order to consider the risk of fracture based on BMD 
values by considering also sexual dimorphism of the skeleton23,44 
and avoiding to transpose to men what we have learnt from women 
without considering differences between the two sexes in terms of 
bone pathophysiology.171 To do this, more stringent criteria based 
on validated male reference ranges for BMD are required in order 
to appropriately diagnose and manage osteoporosis in older men.
Concerning the role of TRT on the prevention of fractures, there 
are no available data. However, TRT is effective in ensuring bone 
anabolism, in preventing sarcopenia, and in improving physical per-
formance and all these effects defend against both frailty and falls, 
that are known factors involved in the occurrence of fractures, es-
pecially the femoral one.40
There is a lack of data concerning both the possible use of es-
trogen treatment in men and in particular in men with hypogonad-
ism.61 At present, we have indirect information on estrogen effects 
on bone from rare cases of men with aromatase deficiency showing 
that physiological doses of exogenous E2 are able to increase BMD 
in a dose-dependent way.62,76 Little is known about the efficacy of 
selective ER modulators (SERMs) in men and suggests that raloxi-
fene is not so effective as E2 in men with aromatase deficiency.172
10  | CONCLUSIONS
The assessment of bone health should be included in the clinical 
workup of men with LOH bearing in mind that osteoporosis is under-
managed and underdiagnosed in older men and remains less inves-
tigated by researchers than in the female counterpart. Bone health, 
in fact, may be considered a rare case of gender health inequality 
favoring women rather than men.2,3 Normative data obtained by 
studies on male population are urgently need for both DXA refer-
ence values and FRAX risk calculation in order to better tailor the 
diagnosis and the follow-up of men with osteoporosis. Andrological 
consultation performed in men with LOH represents an opportunity 
for male health173 including bone.4
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